ArticleAnnals of thoracic surgery short reports2025
Optimal Management of the Cyanotic Neonate With Tetralogy of Fallot-A Clinical Decision Analysis.
Article in Annals of thoracic surgery short reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Management options for critically cyanotic neonates with tetralogy of Fallot include primary repair, ductal or right ventricular outflow tract stents, and surgical shunts. However, rigorous comparisons between these strategies are precluded by small numbers, lack of equipoise, and center-specific bias. Methods: A Markov model decision tree with Monte Carlo microsimulations was constructed to model 2-year outcomes for a hypothetical cohort of 10,000 cyanotic tetralogy of Fallot neonates eligible for all 3 strategies. Input transition state probabilities, utilities, and costs were derived from representative published reports. Outcomes were used to determine quality-adjusted life-years and costs after 50 model iterations. The incremental cost-effectiveness ratio was calculated to determine the preferred strategy. Sensitivity and threshold analysis varied probabilities of 40 factors to identify values at which the preferred strategy would switch. Results: From modeling, immediate mortality from index procedure favored staged approaches, but total mortality favored primary repair after approximately 6 months. Cumulative 2-year mortality from modeling was 8.1%, 11.6%, and 12.4% for primary repair, stenting, and shunting, respectively. Calculated incremental cost-effectiveness ratios identified primary repair as the preferred strategy, followed by stenting and then shunting. Sensitivity and threshold analysis identified total pathway cost to be the only determinant of altered strategy preference with respect to primary repair. For comparisons of staged approaches, several variables reflecting cost and outcomes were identified. Conclusions: Our modeling suggests that primary repair may be superior to staging with stent or shunt for cyanotic neonates with tetralogy of Fallot, with improved 2-year morbidity, mortality, and cost utility.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.